Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Scarboxy-Gel is a topical ophthalmic gel developed and marketed by SCLERA Healthcare (Sclera Health Care Pvt Ltd), an Indian pharmaceutical company. The formulation contains carboxymethylcellulose sodium, a high-molecular-weight polymer that functions as a lubricant and mucomimetic tear substitute. It is designed to increase the viscosity of the tear film and prolong precorneal residence time, providing relief from symptoms of ocular dryness and irritation. By binding to corneal epithelial cells, it helps protect the ocular surface from desiccation and environmental factors. Scarboxy-Gel is primarily used for the management of dry eye syndrome and other ocular conditions requiring enhanced lubrication.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Scarboxy-Gel.